Deaths of five patients unrelated to Hemlibra, Roche says

29 March 2018

Swiss pharma giant Roche (ROG: SIX) has moved to calm any fears relating to its hemophilia A treatment Hemlibra (emicizumab) by stating that the drug was not responsible for the reported deaths of a handful of patients who had been taking it.

The Hemophilia Federation of America published a statement this week, providing information from Roche’s subsidiary Genentech, that five patient deaths had occurred while the patients were using Hemlibra.

Hemlibra is approved in Japan, Europe and the USA as a treatment for hemophilia A patients with inhibitors to factor VIII.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK